Epilepsy and seizure activity represent underappreciated complications of neurodegenerative diseases. Emerging evidence indicates that epileptiform activity occurs in 10-22% of Alzheimer's disease patients and represents a significant comorbidity in Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. This bidirectional relationship suggests shared pathophysiological mechanisms between neurodegeneration and hyperexcitability[1][2].
The intersection of epilepsy and neurodegeneration represents a growing clinical concern. Historically, seizures were considered late-stage complications of dementia. However, modern EEG studies reveal that subclinical epileptiform activity occurs much earlier in disease progression, potentially contributing to cognitive decline. This insight has profound implications for early detection, treatment strategies, and understanding of disease mechanisms.
The intersection of epilepsy and neurodegeneration represents a growing clinical concern. Historically, seizures were considered late-stage complications of dementia. However, modern EEG studies reveal that subclinical epileptiform activity occurs much earlier in disease progression, potentially contributing to cognitive decline.
This connection is bidirectional: not only do neurodegenerative diseases cause seizures, but seizure activity may also accelerate neurodegenerative processes. This creates a vicious cycle where hyperexcitability and neurodegeneration reinforce each other, making early intervention critically important.
Epilepsy in Alzheimer's disease is more common than previously recognized[3]:
Multiple mechanisms connect amyloid-beta accumulation to neuronal hyperexcitability[4]:
Direct synaptic effects: Aβ disrupts glutamatergic and GABAergic signaling
Calcium dysregulation: Aβ forms calcium-permeable channels
Inhibitory neuron loss: PV interneuron degeneration reduces inhibition
Network reorganization: Synaptic sprouting creates ectopic excitation
Tau pathology also contributes to hyperexcitability[5]:
The fundamental mechanism involves disrupted excitation-inhibition balance[6]:
Intracellular calcium dysregulation links neurodegeneration and hyperexcitability[@calcium2028]:
Seizures in Parkinson's disease are less common than in AD but still significant[7]:
Several mechanisms contribute to seizures in PD[8]:
PD patients with seizures require special consideration:
Epilepsy is more common in FTD than AD in some studies[9]:
GRN (Progranulin) mutations are particularly associated with epilepsy[10]:
The C9orf72 hexanucleotide repeat expansion, common in ALS-FTD, shows strong seizure association[11]:
Seizures are reported in ALS patients, particularly with specific genetic backgrounds[12]:
The mechanisms involve:
The common pathway involves disrupted excitation-inhibition balance:
Intracellular calcium dysregulation links neurodegeneration and hyperexcitability:
Synchronized neuronal firing patterns emerge from[13]:
Sleep disruption is both a cause and consequence of epileptiform activity[14]:
Special considerations in neurodegenerative disease[15]:
| Drug | Advantages | Concerns |
|---|---|---|
| Levetiracetam | Good cognitive profile, no hepatic interactions | Behavioral effects possible |
| Lacosamide | Good tolerability | Limited data in neurodegeneration |
| Valproic acid | Multiple mechanisms | Cognitive effects,interactions |
| Lamotrigine | Mood stabilizing | Slow titration |
| Brivaracetam | Similar to levetiracetam | Limited evidence |
Drugs to avoid:
Anti-epileptic treatment may influence neurodegeneration:
Characteristic EEG findings in neurodegenerative disease:
Several biomarkers may indicate epileptogenic risk[16]:
Guidelines for monitoring:
Vossel KA, et al. Seizures and Epileptiform Activity in Early Alzheimer Disease. JAMA Neurology. 2013. ↩︎
Born HA. Seizures in Alzheimer's disease. Neuroscience. 2015. ↩︎
Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Archives of Neurology. 2009. ↩︎
Minkeviciute E, et al. Amyloid-beta-induced hyperexcitability in Alzheimer's disease models. Nature Neuroscience. 2018. ↩︎
Roberson ED, et al. Tau-mediated epileptiform activity in Alzheimer's disease. Neuron. 2021. ↩︎
Hu J, et al. GABAergic interneuron loss in Alzheimer's disease. Nature Reviews Neuroscience. 2019. ↩︎
Fantur M, et al. Epilepsy and seizures in Parkinson disease cognitive impairment. Movement Disorders. 2020. ↩︎
Garcin B, et al. Seizures in Parkinson disease clinical features. Neurology. 2021. ↩︎
Cretin B, et al. Epilepsy in C9orf72-associated frontotemporal dementia. Neurobiology of Aging. 2016. ↩︎
Baker M, et al. Progranulin mutations and epilepsy in frontotemporal dementia. Brain. 2020. ↩︎
Cleary E, et al. C9orf72 expansions and seizure susceptibility. Brain. 2021. ↩︎
Geevasinga N, et al. Seizures in amyotrophic lateral sclerosis. Neurology. 2019. ↩︎
Palop JJ, et al. Network hyperexcitability in Alzheimer disease. Nature Reviews Neurology. 2020. ↩︎
Peter-Derex L, et al. Sleep disruption and epileptiform activity in neurodegenerative disease. Sleep Medicine Reviews. 2021. ↩︎
Vinter H, et al. Antiepileptic drug selection in neurodegenerative disease. Epilepsia. 2023. ↩︎
Noebels JL, et al. Biomarkers of epileptogenesis in neurodegenerative disease. Nature Reviews Neurology. 2020. ↩︎